When everyone sells the same drugs

Noom acquired Tailor Made Compounding on April 1.

Noom bought a 503A licensed pharmacy operating in 46 states. TMC serves 400 clinics and multiple telehealth brands.

The play is retention, not just supply. Owning compounding means Noom controls the formulary and can expand into peptides, NAD+, HRT, and healthy aging without relying on an external partner.

If you still think of Noom as a coaching app, stop. The new Noom is building an LTV machine that moves patients from weight loss into longevity inside one walled garden.

FDA clarified its GLP-1 compounding policy on April 1.

A 503A compounder can still fill four or fewer prescriptions per calendar month for any product that is essentially a copy of an FDA-approved drug. More than that, enforcement is on the table.

This is a ceiling, not a floor. FDA sent 30 warning letters to telehealth brands in early March, and the enforcement posture keeps tightening.

If your brand depends on compounded GLP-1s as a price differentiator, the moat is melting. Retention is what patients will stay for when the price gap closes.

Hims & Hers disclosed a third-party data breach.

Attackers accessed the external customer support platform between February 4-7 and stole support tickets containing personal information.

In telehealth, trust is the asset. Patients share their body, their history, their anxieties. A breach hits harder here than at a SaaS company.

The brands that ride out events like this are the ones with layered patient relationships (subscriptions, provider touchpoints, community). Transactional relationships break at the first sign of risk.

CMS launched the ACCESS Model on April 14.

150 digital health companies were selected for a 10-year chronic care payment program covering telehealth, wearables, and wellness apps for obesity, hypertension, kidney disease, and depression.

Reimbursement is shifting from "covered when billable" to "baked into chronic care." That reshapes unit economics for telehealth brands that can get included downstream.

The brands positioned to win in this model are the ones with structured lifecycle programs, because recurring engagement is exactly what the payment rewards.

When everyone sells the same drugs, retention is the only moat left.

Look at what actually happened in the last 30 days.

Noom bought a pharmacy. Hims closed a $1.15B Eucalyptus acquisition. Walgreens launched a $49 weight loss telehealth program in 28 states. FDA sent 30 warning letters and drew a hard line on compounded GLP-1s.

A few years ago, the differentiator in telehealth was access. Could you even get the drug. Then it became price. Who compounded the cheapest semaglutide.

Now it is becoming clinical legitimacy plus patient experience, because the drugs are turning into commodities and the regulators keep rewriting the supply chain.

If you run a weight loss telehealth brand and your value prop is "we have GLP-1s," you are selling the same thing as every major player in the category. The drug is not the moat.

The moat is what happens after the first shipment.

1. The cross-sell window just got shorter.

Noom and Hims are both pushing patients from GLP-1 into adjacent treatments (NAD+, HRT, peptides, longevity stacks). The pitch now starts around month 2, not month 6.

Because the second order is what separates a profitable patient from an unprofitable one. CAC is climbing 10-15% per year. Single-treatment patients cannot carry those economics.

If your first cross-sell flow still triggers at month 4 or month 6, you are out of sync with the market and the patient journey. The right window is behavior and signal-triggered, not calendar-based.

Start the educational layer as early as weeks 2-4 for side effect support (Zofran, MIC+B12 where clinically appropriate), then introduce the bigger LTV plays (NAD+, Sermorelin, peptides) from week 6 onward as patients show readiness. Universal blasts at a fixed week miss the point.

2. Your onboarding has to survive a supply disruption.

Patients on compounded GLP-1s are reading the same headlines you are. They already know their compounder might get shut down or forced to scale back.

Your onboarding needs to do more than set side effect expectations. It has to build a relationship that holds when supply gets bumpy.

Community. Provider connection. Content that has nothing to do with the medication itself. The patients who stay are the ones who feel like they joined something, not bought something.

3. Trust infrastructure is now a retention asset, not just an acquisition one.

The Hims breach will not hurt Hims long term because their patient relationships are layered (subscriptions, cross-sells, brand touchpoints, provider rapport). A smaller brand with the same breach would lose half its list overnight.

You build that layering through email, SMS, and real content. Weekly educational pieces. Patient spotlights. Founder messages when something goes wrong across the industry.

The technical work (deliverability, segmentation, flow architecture) is the scaffolding. The actual asset is the relationship, and it only compounds through consistent, high-quality contact over months and years.

The takeaway.

When your drug is the same as the market leader's drug, and the regulator keeps rewriting the supply chain, the only durable differentiator is the patient experience you build between refills.

That experience is your lifecycle program. If it is patchy or absent, your business is sitting on top of a moat someone else can drain any time.

The 400-clinic question.

Noom acquired TMC, which supplies 400 clinics and multiple telehealth brands. Those brands now have a direct competitor as their pharmacy.

If you source from a compounder that could get acquired by a DTC competitor, your supply chain is also their market research. Diversify before the call gets made for you.

The Hims breach is a positioning opening.

Every time a category leader stumbles on trust, smaller brands get a rare moment of relevance. A single plain text email from your founder on how your brand handles patient data is the kind of content that earns a reply.

Not opportunistic. Just honest. The brands that communicate like humans during industry turbulence get the next refill without asking for it.

Short vs long email copy in telehealth.

We just finished a test with a telehealth client. Short copy won on clicks, long copy won on click-to-conversions. The right format depends on the stage of the patient journey.

Warm lapsed subscribers respond to plain text, long, provider-voice copy. Prospects mid-questionnaire respond to tight visual emails with one idea and one CTA. Stop looking for one universal answer.

Pull your post-purchase onboarding flow and look at the emails that send between day 90 and day 180.

If it is a generic check-in ("How are you feeling?") with no clinical angle, that slot is doing nothing. That window is where GLP-1 patients actually hit plateau anxiety, start comparing themselves to competitor transformations, and go shopping for an excuse to pause or cancel.

Replace it with a provider-voice, plain-text email that reframes progress around non-scale wins (energy, sleep, clothes fitting, bloodwork) and names the plateau directly. Subject line pattern that works: "It's OK if GLP-1 feels slow right now."

30 minutes to write. 10 minutes to ship. We see this single change lift month 3-6 retention on almost every brand where the slot was empty before.

If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz

Reply to this with your biggest retention challenge. I read and respond to every single one.